10-Q: Avalon GloboCare Reports Deepening Losses, Going Concern Warning

Avalon GloboCare Corp. reported a substantial increase in net loss for Q2 and H1 2025, alongside a significant working capital deficit, raising substantial doubt about its ability to continue as a going concern.

Summary

• Net loss for the three months ended June 30, 2025, increased by 531.3% to $13.46 million, and for the six months ended June 30, 2025, by 355.5% to $15.94 million, compared to the prior year periods.
• The working capital deficit worsened by 32.7% to $14.13 million at June 30, 2025, from $10.65 million at December 31, 2024.
• The cash balance significantly decreased to $201,532 at June 30, 2025, from $2.86 million at December 31, 2024.
• A $9.08 million loss on extinguishment of debt was recorded due to a reduction in the conversion price of the June 2024 Convertible Note.
• A credit loss expense of $1.65 million was recognized for the receivable from the sale of the equity method investment in Lab Services MSO.
• The 40% equity interest in Lab Services MSO was redeemed on February 26, 2025, to preserve cash, resulting in income from equity method investment of $392,677 for the six months ended June 30, 2025.
• Real property rental revenue increased by 6.9% to $350,406 for the three months ended June 30, 2025, and by 9.0% to $700,206 for the six months ended June 30, 2025.
• Professional fees surged by 232.1% to $1.48 million for the three months ended June 30, 2025, and by 257.2% to $3.17 million for the six months ended June 30, 2025, largely due to a potential merger with YOOV Group Holding Limited.
• Research and development efforts related to cellular therapy have been suspended to preserve cash and focus on core business strategies.
• Disclosure controls and procedures were deemed ineffective as of June 30, 2025, due to un-remediated material weaknesses.

Sentiment

Score: 2

Explanation: The company faces severe financial distress, evidenced by a significant increase in net losses, a rapidly dwindling cash balance, a substantial working capital deficit, and an explicit 'going concern' warning. While there are minor positive operational improvements in real estate, these are overshadowed by large debt-related expenses, credit losses, and high professional fees associated with potential mergers and ongoing capital raises, which are often on unfavorable terms. The ineffectiveness of disclosure controls adds to the negative sentiment.

Positives

• Real property rental revenue increased by 6.9% to $350,406 for the three months ended June 30, 2025, and by 9.0% to $700,206 for the six months ended June 30, 2025, driven by higher occupancy (96.2% at June 30, 2025).
• Real property operating income increased by 134.3% to $99,329 for the three months ended June 30, 2025, and by 79.8% to $168,739 for the six months ended June 30, 2025.
• The redemption of the 40% equity interest in Lab Services MSO resulted in income from equity method investment of $392,677 for the six months ended June 30, 2025, and was executed to preserve cash.
• Directors and officers liability insurance premium decreased by 48.1% for the three months ended June 30, 2025, and 48.4% for the six months ended June 30, 2025, due to switching providers.
• Miscellaneous taxes decreased by 80.1% for the three months ended June 30, 2025, and 66.6% for the six months ended June 30, 2025, due to decreased Delaware state franchise tax.

Negatives

• Net loss significantly widened to $13.46 million for the three months ended June 30, 2025, and $15.94 million for the six months ended June 30, 2025.
• Cash balance plummeted by over 92% from $2.86 million at December 31, 2024, to $201,532 at June 30, 2025.
• Working capital deficit increased by $3.49 million to $14.13 million.
• A $9.08 million loss on extinguishment of debt was recognized due to a reduction in the conversion price of the June 2024 Convertible Note.
• A $1.65 million credit loss expense was recorded for the receivable from the sale of Lab Services MSO.
• Professional fees increased substantially by $1.03 million (232.1%) for the three months ended June 30, 2025, and $2.28 million (257.2%) for the six months ended June 30, 2025, largely due to potential merger activities.
• Advertising and marketing expenses increased by $259,892 (414.8%) for the three months ended June 30, 2025, and $286,042 (265.7%) for the six months ended June 30, 2025.
• Total (Deficit) Equity shifted from positive $7.10 million at December 31, 2024, to negative $7.11 million at June 30, 2025.
• Net cash used in operating activities increased to $3.03 million for the six months ended June 30, 2025, from $2.00 million for the six months ended June 30, 2024.
• Net cash provided by financing activities decreased significantly to $277,636 for the six months ended June 30, 2025, from $2.01 million for the six months ended June 30, 2024.

Risks

• Substantial doubt about the company's ability to continue as a going concern due to recurring net losses, negative operating cash flow, and a significant working capital deficit.
• Inability to raise additional capital through equity or debt on satisfactory terms, or at all, which could restrict growth or force cessation of operations.
• Material weaknesses in disclosure controls and procedures, indicating a risk of misstated financial information.
• Dependence on generating rental revenue from a single real estate property and revenue from KetoAir sales.
• Litigation risk from Research Institute at Nationwide Children's Hospital with an accrued settlement of $373,450.
• Uncertainty regarding the finalization of the License Agreement for Avactis's cellular immunotherapy technology and intellectual property.
• Potential for unexpected costs and expenses or cash requirements that could necessitate alternative financing.
• Dilution of existing stockholders if additional equity or debt securities are issued.
• Impact of an inflationary environment and tariffs on economic conditions.

Future Outlook

The company expects real property rental revenue and operating income to remain at current levels with minimal increases. Advertising and marketing expenses are also expected to remain at current quarterly levels with minimal increases. Professional fees are anticipated to decrease in the near future. Cash used in operating activities is projected to increase in the next 12 months due to new product development, commercialization, and expanded public relations/sales promotions. The company plans to raise additional capital through equity or debt sales to fund operations, but there is no assurance such financing will be available on satisfactory terms.

Management Comments

• Our continued growth is dependent upon the continuation of generating rental revenue from our income-producing real estate property in New Jersey, generating revenue for selling of Keto Air, and obtaining additional financing to fund future obligations and pay liabilities arising from normal business operations.
• The current cash balance cannot be projected to cover our operating expenses for the next twelve months from the release date of this report.
• These matters raise substantial doubt about our ability to continue as a going concern.
• We plan on raising capital through the sale of equity to implement our business plan. However, there is no assurance these plans will be realized and that any additional financings will be available to us on satisfactory terms and conditions, if any.
• We expect that our revenue from real property rental will remain at its current level with minimal increase in the near future.
• We expect that our advertising and marketing expenses will likely remain at its current quarterly level with minimal increase in the near future.
• We expect that our professional fees will decrease in the near future.
• We expect that our compensation and related benefits will likely remain at its current quarterly level with minimal increase in the near future.
• We expect that our miscellaneous taxes will remain relatively steady, with minimal increase, in the near future.
• We expect our cash used in operating activities to increase in the next 12 months due to the development and commercialization of new products; and an increase in public relations and/or sales promotions for existing and/or new brands as we expand within existing markets or enter new markets.
• The inability to obtain additional capital may restrict our ability to grow and may reduce our ability to continue to conduct business operations. If we are unable to obtain additional financing, we will be required to cease our operations. To date, we have not considered this alternative, nor do we view it as a likely occurrence.

Industry Context

The company is pivoting its focus from cellular therapy R&D to commercializing its KetoAir breathalyzer device, targeting the diabetes and obesity markets. This shift, coupled with the divestment of its laboratory testing services segment, indicates a strategic realignment towards more immediate revenue-generating consumer products and its existing real estate operations, away from capital-intensive biotech R&D. The company's financial struggles, including a 'going concern' warning, suggest it is operating in a challenging capital environment, potentially impacting its ability to compete effectively in both the diagnostic device and real estate sectors.

Corporate Governance

Legal Proceedings

• Ongoing lawsuit by Research Institute at Nationwide Children's Hospital for misappropriation of trade secrets, with an accrued litigation settlement of $373,450 as of June 30, 2025.
• Company filed a lawsuit against Laboratory Services MSO, LLC and affiliates on July 22, 2025, for breach of contract related to the Redemption and Abandonment Agreement, but the parties have agreed to a settlement in principle.

Related Party Transactions

• Rental revenue of $12,600 for Q2 2025 and $25,200 for H1 2025 from D.P. Capital Investments LLC, controlled by Chairman Wenzhao Lu.
• Consulting expenses of $15,197 for Q2 2025 and $30,794 for H1 2025 paid to Wilbert Tauzin (director) and his son.
• Unpaid acquisition consideration of $100,000 to Dr. Yu Zhou (former director and co-CEO) for Beijing Jieteng (Genexosome) Biotech Co., Ltd. acquisition.
• Advance of $3,258,078 received from Mr. Lu for the pending sale of 30% of Avalon RT 9.
• Exchange of 9,000 shares of Series A Preferred Stock (carrying value $9,000,000) for 5,000 shares of Series D Preferred Stock by Wenzhao Lu, resulting in a deemed contribution of $162,473.

Stakeholder Impact

• Shareholders: Significant dilution risk from ongoing and future equity raises, substantial losses, negative equity, and a 'going concern' warning. Share price likely to be negatively impacted.
• Creditors: Increased risk due to worsening financial condition, high working capital deficit, and reliance on future financing. Convertible note holders have converted debt at a reduced price, indicating unfavorable terms for the company.
• Employees: Potential uncertainty regarding job security given the company's financial distress and strategic shifts (e.g., suspension of cellular therapy R&D, dissolution of dormant subsidiaries).
• Customers (KetoAir): Continued focus on commercialization of KetoAir, but overall financial instability could impact long-term product support or development.
• Tenants (Real Estate): Stable rental revenue, but the pending sale of a noncontrolling interest in the property could introduce changes in management or ownership structure.

Next Steps

• Continue commercialization and development of the KetoAir breathalyzer system.
• Develop additional diagnostic uses of the breathalyzer technology.
• Advance intellectual property portfolio through existing patent applications.
• Raise additional capital through equity or debt sales.
• Remediate material weaknesses in disclosure controls and procedures.
• Close the acquisition of 30% of Avalon RT 9 by Mr. Lu in Q4 2025.
• Finalize the License Agreement for Avactis's cellular immunotherapy technology with Arbele Biotherapeutics.
• Respond to the lawsuit filed against Laboratory Services MSO, LLC (though settlement in principle is noted).

Key Dates

Recommendation

The company's financial position is severely distressed, marked by a substantial increase in net losses, a critical decline in cash reserves, and a significant working capital deficit, leading to an explicit 'going concern' warning. The $9.08 million loss on extinguishment of debt and $1.65 million credit loss expense highlight significant financial challenges. While real estate operations show minor improvements, they are insufficient to offset the overall deterioration. The company's reliance on continuous capital raises, often on dilutive terms, and the acknowledged ineffectiveness of disclosure controls further erode investor confidence. The suspension of cellular therapy R&D indicates a retreat from a potentially high-growth but capital-intensive area. Given the severe financial instability, high operational burn rate, and significant dilution risk, a strong sell recommendation is warranted.

Keywords

Avalon GloboCare, ALBT, 10-Q, Quarterly Report, Biotechnology, Diagnostics, KetoAir, Breathalyzer, Real Estate, Financial Results, Net Loss, Working Capital Deficit, Going Concern, SEC Filing, Cellular Therapy, Corporate Governance, Capital Raise, Litigation